4 not yet recruiting, 2 recruiting. 3 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 3 |
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Luvometinib: new trials by email Literature Review of Luvometinib trials Research Report on Luvometinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis Luvometinib, Luvometinib, Cytarabine. - Langerhans Cell Histiocytosis | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 30 | 2026-06-30 | 2026-07-27 |
| Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions Luvometinib - Langerhans Cell Histiocytosis (LCH) | Not applicable | Recruiting | West China Second University Hospital | 62 | 2026-06-19 | 2026-01-27 |
| Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis Prednisone, Vincristine, Mercaptopurine - Langerhans Cell Histiocytosis (LCH) | Not applicable | Recruiting | West China Second University Hospital | 120 | 2026-02-13 | 2026-02-24 |
| FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration Luvometinib, Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide - Low-grade Glioma, Pediatric Low-grade Gliomas | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-06-30 | 2025-06-04 |
Histiocytosis, Langerhans-Cell (3) · Meningioma (2) · Neurofibromatosis 2 (2) · Neuroma, Acoustic (2) · Ependymoma (1)
Beijing Tiantan Hospital (2) · West China Second University Hospital (2) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
China (6)
PMID 31513482, PMID 32106306, PMID 36884302, PMID 37731389, PMID 40167581, PMID 40751881, PMID 41035796, PMID 15049016, PMID 23109216, PMID 29263218, PMID 29594922, PMID 30693828, PMID 33958797, PMID 37216396, PMID 38231288, PMID 38501389, PMID 38501390, PMID 41135521